Future advances in pulmonary arterial hypertension
Over the last decade has witnessed extensive progress in basic and clinical research in the field of pulmonary arterial hypertension (PAH). International PAH registries have achieved much to advance our understanding of the epidemiology, demographics, etiology, clinical course, hemodynamics, disease...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés Español |
| Publicado: |
2013
|
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 13444caa a22010217a 4500 | ||
|---|---|---|---|
| 001 | PAPER-24142 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205556.0 | ||
| 008 | 190411s2013 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-84891550737 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 041 | 0 | |a eng |a spa | |
| 100 | 1 | |a Bevacqua, R.J. | |
| 245 | 1 | 0 | |a Future advances in pulmonary arterial hypertension |
| 246 | 3 | 1 | |a Avances futuros en la hipertensión arterial pulmonar |
| 260 | |c 2013 | ||
| 270 | 1 | 0 | |m Perrone, S. V.Montañeses 2325, CP: C1428AQK, Ciudad Autónoma de Buenos Aires, Argentina; email: svperrone@netizen.com.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Simonneau, G., Robbins, I.M., Beghetti, M., Updated Clinical Classification of Pulmonary Hypertension (2009) J Am Coll Cardiol, 54, pp. S43-54 | ||
| 504 | |a Melero, M.J., Estado actual de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 23-26 | ||
| 504 | |a Naval, N., Epidemiologia de la hipertensión pulmonar (2010) Insuf Card, 5 (4), pp. 192-196 | ||
| 504 | |a Bevacqua, R.J., Bortman, G., Perrone, S.V., Antagonistas de los receptores de la endotelina para la hipertensión arterial pulmonar (2013) Insuf Card, 8 (2), pp. 77-94 | ||
| 504 | |a Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) (2010) Circulation, 122, pp. 164-172 | ||
| 504 | |a Badesch, D.B., Raskob, G.E., Elliott, C.G., Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry (2010) Chest, 137, pp. 376-387 | ||
| 504 | |a Humbert, M., Sitbon, O., Chaouat, A., Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era (2010) Circulation, 122, pp. 156-163 | ||
| 504 | |a Humbert, M., Sitbon, O., Yaici, A., Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension (2010) Eur Respir J, 36, pp. 549-555 | ||
| 504 | |a Humbert, M., Sitbon, O., Chaouat, A., Pulmonary arterial hypertension in France: Results from a national registry (2006) Am J Respir Crit Care Med, 173, pp. 1023-1030 | ||
| 504 | |a Hurdman, J., Condliffe, R., Elliot, C.A., ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre (2012) Eur Respir J, 39, pp. 945-955 | ||
| 504 | |a Pepke-Zaba, J., Delcroix, M., Lang, I., Chronic thromboembolic pulmonary hypertension (CTEPH): Results from an international prospective registry (2011) Circulation, 124, pp. 1973-1981 | ||
| 504 | |a Humbert, M., Sitbon, O., Simonneau, G., Treatment of pulmonary arterial hypertension (2004) N Engl J Med, 351, pp. 1425-1436 | ||
| 504 | |a O'Callaghan, D.S., Savale, L., Montani, D., Treatment of pulmonary arterial hypertension with targeted therapies (2011) Nat Rev Cardiol, 8, pp. 526-538 | ||
| 504 | |a Galiè, N., Hoeper, M.M., Humbert, M., Guidelines for the diagnosis and treatment of pulmonary hypertension (2009) Eur Respir J, 34, pp. 1219-1263 | ||
| 504 | |a Galiè, N., Hoeper, M.M., Humbert, M., Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) (2009) Eur Heart J, 30, pp. 2493-2537 | ||
| 504 | |a Naval, N., Clasificación actual de la hipertensión pulmonar (2011) Insuf Card, 6 (1), pp. 30-38 | ||
| 504 | |a Bortman, G., Presentación clínica y clasificación actual de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 27-32 | ||
| 504 | |a Simonneau, G., Robbins, I.M., Beghetti, M., Updated clinical classification of pulmonary hypertension (2009) J Am Coll Cardiol, 54 (SUPPL. 1), pp. S43-S54 | ||
| 504 | |a Humbert, M., Souza, R., Galiè, N., McLaughlin, V., Simonneau, G., Rubin, L., Pulmonary arterial hypertension: Bridging the present to the future (2012) Eur Respir Rev, 21, pp. 126+267-270 | ||
| 504 | |a Bichara, V.M., Ventura, H.O., Perrone, S.V., Hipertensión pulmonar: La mirada del especialista (2011) Insuf Card, 6, pp. 65-79 | ||
| 504 | |a Mazzei, J.A., Cáneva, J.O., Perrone, S.V., Melero, M.J., Scali, J.J., Bortman, G., Actualización en el diagnostico y tratamiento de la hipertensión pulmonar (2011) Medicina (B Aires), 71 (SUPPL. 1), pp. 1-48 | ||
| 504 | |a Caroli, C., Yaman, B., Embón, M., Cohen Arazi, H., Perrone, S.V., Resonancia magnética nuclear en la evaluación de la hipertensión pulmonar (2009) Insuf Card, 4 (2), pp. 82-84 | ||
| 504 | |a Perrone, S.V., Estrategia terapéutica en el tratamiento de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 33-43 | ||
| 504 | |a Mazzei, J.A., Hipertensión pulmonar en las enfermedades respiratorias crónicas. Prueba de marcha de 6 minutos: Técnica y utilidad en el diagnóstico funcional, pronóstico y seguimiento (2013) Insuf Card, 8 (3), pp. 125-133 | ||
| 504 | |a Mazzei, J.A., Mecanismos fisiopatológicos involucrados y diagnóstico de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 3-10 | ||
| 504 | |a Condliffe, R., Kiely, D.G., Peacock, A.J., Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era (2009) Am J Respir Crit Care Med, 179, pp. 151-157 | ||
| 504 | |a Dimopoulos, K., Inuzuka, R., Goletto, S., Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension (2010) Circulation, 121, pp. 20-25 | ||
| 504 | |a Vachiéry, J.-L., Gaine, S., Challenges in the diagnosis and treatment of pulmonary arterial hypertension (2012) Eur Respir Rev, 21, pp. 313-320 | ||
| 504 | |a Galiè, N., Rubin, L.J., Hoeper, M., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial (2008) Lancet, 371, pp. 2093-2100 | ||
| 504 | |a Frost, A.E., Badesch, D.B., Barst, R.J., The changing picture of patients with pulmonary arterial hypertension in the United States: How REVEAL differs from historic and non-US Contemporary Registries (2011) Chest, 139, pp. 128-137 | ||
| 504 | |a Barimboim, E., Hipertensión pulmonar en las enfermedades del tejido conectivo: Nuevas perspectivas ante un problema de difícil resolución (2009) Insuf Card, 4 (3), pp. 101-106 | ||
| 504 | |a Sánchez Román, J., Diagnostico y tratamiento de la hipertensión pulmonar en pacientes con esclerodermia (2012) Insuf Card, 7 (1), pp. 16-28 | ||
| 504 | |a Humbert, M., Yaici, A., de Groote, P., Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival (2011) Arthritis Rheum, 63, pp. 3522-3530 | ||
| 504 | |a Humbert, M., Coghlan, J.G., Khanna, D., Early detection and management of pulmonary arterial hypertension (2012) Eur Respir Rev, 21, pp. 306-312 | ||
| 504 | |a Bichara, V.M., Tazar, J., Ventura, H.O., El ecocardiograma como herramienta para el diagnóstico y la evaluación de los pacientes con insuficiencia cardíaca (2010) Insuf Card, 5 (2), pp. 51-58 | ||
| 504 | |a Tazar, J., Haurigot, M.P., Caram, R., Haurigot, G.E., Función sistólica del ventrículo derecho en pacientes con hipertensión pulmonar: Análisis con strain y strain rate (2012) Insuf Card, 7 (3), pp. 109-116 | ||
| 504 | |a Lauga, A., D'Ortencio, A., Monitoreo de las presiones de la arteria pulmonar: Catéter de Swan-Ganz. Parte I (2007) Insuf Card, 2 (1), pp. 5-11 | ||
| 504 | |a Launay, D., Sitbon, O., Le Pavec, J., Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil (2010) Rheumatology (Oxford), 49, pp. 490-500 | ||
| 504 | |a Grignola, J.C., Gómez Sánchez, M.A., Bosentan: Rol en el tratamiento de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 11-22 | ||
| 504 | |a Kaplinsky, E.J., Utilidad del bosentán en la hipertensión pulmonar tromboembólica crónica: Estudio BENEFIT (2008) Insuf Card, 3 (2), pp. 63-64 | ||
| 504 | |a Hoeper, M.M., Markevych, I., Spiekerkoetter, E., Goal-oriented treatment and combination therapy for pulmonary arterial hypertension (2005) Eur Respir J, 26, pp. 858-863 | ||
| 504 | |a Barst, R.J., Miller, D.P., Beery, F., Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry (2011) Am J Respir Crit Care Med, 183, pp. A5941 | ||
| 504 | |a McLaughlin, V.V., Shillington, A., Rich, S., Survival in primary pulmonary hypertension: The impact of epoprostenol therapy (2002) Circulation, 106, pp. 1477-1482 | ||
| 504 | |a Nickel, N., Golpon, H., Greer, M., The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension (2012) Eur Respir J, 39, pp. 589-596 | ||
| 504 | |a Sitbon, O., Humbert, M., Nunes, H., Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival (2002) J Am Coll Cardiol, 40, pp. 780-788 | ||
| 504 | |a Sitbon, O., Morrell, N.W., Pathways in pulmonary arterial hypertension: The future is here (2012) Eur Respir Rev, 21, pp. 321-327 | ||
| 504 | |a Iglarz, M., Binkert, C., Morrison, K., Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist (2008) J Pharmacol Exp Ther, 327, pp. 736-745 | ||
| 504 | |a Iglarz, M., Landskroner, K., Rey, M., Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension (2011) Am J Respir Crit Care Med, 183, pp. A6445 | ||
| 504 | |a Raja, S.G., Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis (2010) Curr Opin Investig Drugs, 11, pp. 1066-1073 | ||
| 504 | |a Grimminger, F., Weimann, G., Frey, R., First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension (2009) Eur Respir J, 33, pp. 785-792 | ||
| 504 | |a Ghofrani, H.A., Morrell, N.W., Hoeper, M.M., Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy (2010) Am J Respir Crit Care Med, 182, pp. 1171-1177 | ||
| 504 | |a Thierer, J., Importancia del diagnostico precoz en la hipertensión pulmonar (2009) Insuf Card, 4 (2), pp. 52-58 | ||
| 520 | 3 | |a Over the last decade has witnessed extensive progress in basic and clinical research in the field of pulmonary arterial hypertension (PAH). International PAH registries have achieved much to advance our understanding of the epidemiology, demographics, etiology, clinical course, hemodynamics, disease management and treatment outcomes of PAH. Therapies available to target the pathophysiology of PAH have expanded considerably and more options are expected in the near future. However, the long-term prognosis for patients with PAH remains poor. Recent evidence suggests that World Health Organization functional (WHO) class I or II patients have significantly better long-term survival rates than WHO functional class III-IV patients, thus providing a rationale for earlier diagnosis and treatment of PAH. However, early diagnosis is challenging and there is frequently a delay between symptom onset and diagnosis. Screening programs have an important role in PAH detection and expert opinion favours echocardiographic screening of asymptomatic patients who may be predisposed to the development of PAH. © 2013 Silver Horse. |l eng | |
| 593 | |a División Cardiología, Pabellón Inchauspe, Hospital General de Agudos 'Dr. José María Ramos Mejía', GCBA, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Insuficiencia cardíaca, Hipertensión pulmonar, Trasplante cardíaco, Instituto FLENI, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Instituto Argentino de Diagnóstico y Tratamiento, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Hospital Alta Complejidad en Red El Cruce 'Dr. Néstor Carlos Kirchner', Florencio Varela, Buenos Aires, Argentina | ||
| 593 | |a Instituto Cardiovascular Lezica, San Isidro, Buenos Aires, Argentina | ||
| 593 | |a Hospital Italiano de Mendoza, Mendoza, Argentina | ||
| 690 | 1 | 0 | |a EARLY DIAGNOSIS |
| 690 | 1 | 0 | |a PULMONARY ARTERIAL HYPERTENSION |
| 690 | 1 | 0 | |a SCREENING |
| 700 | 1 | |a Perrone, S.V. | |
| 773 | 0 | |d 2013 |g v. 8 |h pp. 185-190 |k n. 4 |p Insuficiencia Cardiaca |x 18501044 |w (AR-BaUEN)CENRE-8510 |t Insuficiencia Cardiaca | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891550737&partnerID=40&md5=fd15e2976ce1145fd1f86d8cc8ff8b70 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_18501044_v8_n4_p185_Bevacqua |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v8_n4_p185_Bevacqua |y Registro en la Biblioteca Digital |
| 961 | |a paper_18501044_v8_n4_p185_Bevacqua |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 85095 | ||